Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany

BACKGROUND: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by muscle weakness and muscle atrophy. Nusinersen acts as a splicing modifier and has recently been approved for intrathecal treatment of SMA. OBJECTIVE: Prior to approval, nusinersen was provided to patients with SM...

Descripción completa

Detalles Bibliográficos
Autores principales: Pechmann, Astrid, Langer, Thorsten, Schorling, David, Stein, Sabine, Vogt, Sibylle, Schara, Ulrike, Kölbel, Heike, Schwartz, Oliver, Hahn, Andreas, Giese, Kerstin, Johannsen, Jessika, Denecke, Jonas, Weiß, Claudia, Theophil, Manuela, Kirschner, Janbernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2018
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004898/
https://www.ncbi.nlm.nih.gov/pubmed/29689734
http://dx.doi.org/10.3233/JND-180315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004898/
https://www.ncbi.nlm.nih.gov/pubmed/29689734
http://dx.doi.org/10.3233/JND-180315

Ejemplares similares